Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura | Zendy

Claudia Tersteeg | Zendy; Alexandra Schiviz | Zendy; Simon F. De Meyer | Zendy; Barbara Plaimauer | Zendy; Friedrich Scheiflinger | Zendy; Hanspeter Rottensteiner | Zendy; Karen Vanhoorelbeke | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura

Author(s) -

Claudia Tersteeg,

Alexandra Schiviz,

Simon F. De Meyer,

Barbara Plaimauer,

Friedrich Scheiflinger,

Hanspeter Rottensteiner,

Karen Vanhoorelbeke

Publication year - 2015

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.115.306014

Subject(s) - adamts13 , thrombotic thrombocytopenic purpura , medicine , recombinant dna , immunology , platelet , biology , biochemistry , gene

The metalloprotease ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) regulates the size of von Willebrand factor multimers. A deficiency in ADAMTS13 activity is associated with the life-threatening disease thrombotic thrombocytopenic purpura (TTP). The vast majority of patients have acquired TTP, where circulating anti-ADAMTS13 autoantibodies are causative for the decreased ADAMTS13 activity. Current treatment consists of plasma exchange, but improved therapies are highly warranted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research